Why isn't an observed adverse event enough?

Without a comparator it may reflect the treatment, the underlying condition, or chance. Spontaneous reports have a numerator and no denominator.

What does identifying a mechanism achieve?

It converts a correlation into a prediction that can be tested, and explains why events cluster where they do.

Why do most signals never reach quantification?

It requires the event to be recorded consistently across enough trials to pool, or trials large enough to detect it directly.

GLP-1 & Incretin Science

The Gallbladder Case Is Unusually Complete

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

A safety signal becomes knowledge through three stages: consistent observation, an identified mechanism, and a quantified estimate. The gallbladder signal with GLP-1 receptor agonists has all three, which is unusual and makes it a useful template.

Key facts

Stage 1: Consistent observation across trials
Stage 2: Identified mechanism — CCK suppression
Stage 3: Quantified by pooled meta-analysis
Most signals reach: Stage 1 only
Contrast: Thyroid C-cell — mechanism, no human signal
Contrast: Disproportionality reports — signal, no denominator

Why observation alone is weak

An adverse event occurring during treatment may be caused by the treatment, by the condition being treated, or by nothing related. Without a comparator the observation carries almost no information, which is the fundamental limitation of spontaneous reporting systems — they have a numerator and no denominator.

What a mechanism adds

Plausibility and prediction. Knowing that GLP-1 suppresses cholecystokinin, and that cholecystokinin drives gallbladder emptying, explains why the events cluster where they do and predicts that they should. A mechanism converts a correlation into an expectation that can be tested rather than merely noted.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

What quantification adds

Magnitude. Neither an observation nor a mechanism tells you how often. Pooling randomised trials produces an estimate with a confidence interval, which is what turns a described hazard into something that can be weighed against benefit. Without it, a real but rare effect and a real but common one look identical.

Why most signals stop earlier

Mechanisms are hard. Many adverse effects have no identified mediator, and quantification requires either very large trials or pooling enough of them, which depends on the event being recorded consistently across studies that were designed for something else. Reaching all three stages needs the event to be frequent enough to pool and specific enough to trace.

The contrasting cases on this site

The thyroid C-cell warning has a mechanism in rodents and a species difference in receptor expression, but no corresponding human signal — mechanism without observation. Pharmacovigilance disproportionality measures produce signals with no denominator — observation without quantification. The gallbladder case has all three, and that completeness is what makes it exceptional rather than typical.

How to use this when reading any safety claim

Ask which stages a claim rests on. A mechanism alone predicts; it does not demonstrate. An observation alone describes; it does not attribute. Only the combination supports a statement about how much risk a real drug carries, and most published safety discussion has fewer than three legs to stand on.

Quick reference

Case	Observation	Mechanism	Quantified
Gallbladder events	Yes	Yes — CCK suppression	Yes — pooled RCTs
Thyroid C-cell	Rodent only	Yes, species-limited	Human data null
Disproportionality signals	Yes	Often not	No denominator

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Why isn't an observed adverse event enough?: Without a comparator it may reflect the treatment, the underlying condition, or chance. Spontaneous reports have a numerator and no denominator.
What does identifying a mechanism achieve?: It converts a correlation into a prediction that can be tested, and explains why events cluster where they do.
Why do most signals never reach quantification?: It requires the event to be recorded consistently across enough trials to pool, or trials large enough to detect it directly.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum